Skip to main content
. 2013 May 3;8(5):e62627. doi: 10.1371/journal.pone.0062627

Figure 7. Effect of co-treatment with tunicamycin and celecoxib on the expression of COX-2 and CHOP in HepG2 cells.

Figure 7

HepG2 cells were treated with 3 µmol/L tunicamycin in either the absence (control) or the presence of celecoxib (50 µmol/L) for 8 hr. (A)Equal amounts of cell lysates were subjected to western blot analysis using specific anti-COX-2 and anti-CHOP antibody. β-actin in the same HepG2 cells extract was used as an internal used as an internal reference. Optical density reading values of the specific protein versus the loading control protein β-actin are represented as fold of the control values. (*P<0.05, **P<0.01, compared with untreated HepG2 cells, #P<0.05, ##P<0.01, compared with HepG2 cells treated with tunicamycin alone). (B) RNA was harvested and gene expression examined by qRT-PCR. The qRT-PCR fold-changes were normalised using the expression of a housekeeping gene (GAPDH) and compared with those obtained from untreated HepG2 cells.Data are presented as mean ± SD for the three independent experiments. (**P<0.01 compared with untreated HepG2 cells, ##P<0.01 compared with HepG2 cells pretreated with tunicamycin).